Slingshot members are tracking this event:

Allergen Submits Filing to FDA for the Generic Manufacturing and Marketing of Celgene's Abraxane - Celgene to Defend it's Patent Rights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Celgene was notified that Actavis LLC (acquired Allergen in early 2015 and adopted the Allergen corporate name) had filed an Abbreviated New Drug Application to the FDA for the manufacturing and marketing of a generic Abraxane.  Celgene plans to "vigorously defend its extensive intellectual property rights relating to Abraxane".  Abraxane is indicated for the treatment of different types of cancer, including breast cancer and small-cell lung cancer.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Abbreviated New Drug Application, Fda, Abraxane, Patent Rights, Generic Drug